Selected article for: "case definition and study period"

Author: Tavakoli, Ahmad; Karbalaie Niya, Mohammad Hadi; Bokharaei-Salim, Farah; Farahmand, Mohammad; Izadi, Morteza; Dorostkar, Ruhollah; Keyvani, Hossein
Title: The molecular epidemiology of respiratory viruses in military trainees in Iran
  • Document date: 2019_5_8
  • ID: txsjrcs3_5
    Snippet: Study participants were symptomatic military trainees in the basic military training camp of the General Staff of the Armed Forces of the Islamic Republic of Iran. All trainees with symptoms of respiratory tract infection including oral temperature of ≥38°C, cough, sore throat, rhinorrhea, etc. referred to the military medical clinic center were included in this study. Exclusion criteria were a prior history of chronic respiratory disease such.....
    Document: Study participants were symptomatic military trainees in the basic military training camp of the General Staff of the Armed Forces of the Islamic Republic of Iran. All trainees with symptoms of respiratory tract infection including oral temperature of ≥38°C, cough, sore throat, rhinorrhea, etc. referred to the military medical clinic center were included in this study. Exclusion criteria were a prior history of chronic respiratory disease such as asthma and chronic obstructive pulmonary disease (COPD), recent antiviral therapy, and military personnel. Those trainees meeting the case definition received a written and verbal briefing and were invited to give voluntary and informed consent to participate. This cross-sectional study was designed to enroll 400 subjects over a period of 3‏ months, from January to March 2017. This study has been approved by the Ethics Committee of Iran University of Medical Sciences under the Ethics Code IR.IUMS.REC1394.26051. Throat or nasopharyngeal swab specimens of patients were collected by Dacron swabs, placed in viral transport media and stored at −70°C until use.

    Search related documents:
    Co phrase search for related documents
    • antiviral therapy and chronic COPD obstructive pulmonary disease: 1, 2
    • antiviral therapy and chronic COPD obstructive pulmonary disease asthma: 1
    • antiviral therapy and COPD obstructive pulmonary disease: 1, 2
    • antiviral therapy and cross sectional study: 1, 2, 3, 4, 5
    • antiviral therapy and informed voluntary consent: 1
    • antiviral therapy and month period: 1, 2, 3, 4, 5, 6, 7
    • antiviral therapy and nasopharyngeal patient swab specimen: 1
    • antiviral therapy and obstructive pulmonary disease: 1, 2, 3, 4, 5, 6, 7, 8
    • antiviral therapy and patient swab specimen: 1
    • antiviral therapy and prior history: 1, 2
    • antiviral therapy and pulmonary disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • antiviral therapy and recent antiviral therapy: 1, 2, 3, 4, 5, 6, 7, 8
    • antiviral therapy and respiratory disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
    • antiviral therapy and sore throat: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • antiviral therapy and study include: 1, 2
    • antiviral therapy and study participant: 1
    • antiviral therapy and swab specimen: 1, 2, 3
    • antiviral therapy and tract infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
    • case definition and chronic COPD obstructive pulmonary disease: 1